series-b
Stage
1
Investors
About
Sidewinder Therapeutics develops bispecific antibody-drug conjugates that target two receptor complexes on cancer cells simultaneously to increase tumor specificity and enhance delivery of toxic payloads for treatment of cancers with limited therapeutic options.
Explore Sidewinder Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.